Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice
by Guerrero et al.This study shows that treatment of mice with favipiravir (150 mg/kg/dose, BID, oral gavage) significantly reduced viral load in blood and tissues and significantly delayed virus-induced disease. The USUV mouse model is amenable for assessing the potential in vivo efficacy of (novel) USUV/flavivirus inhibitors.
13th November 2018 •
comment